BioWorld

Oct. 19, 2005

Sonus, Schering In Tocosol Paclitaxel Deal Worth $168M

After starting a pivotal trial last month, Sonus Pharmaceuticals Inc. now has secured a sweet deal for its cancer product Tocosol Paclitaxel, giving exclusive worldwide rights to Schering AG. (BioWorld Today) Read More

Genzyme Beats Estimates, CEO Reports Excellent' Third Quarter

Lorus' Shares Take Plunge On Phase III Virulizin Data

Kosan Stops Prostate Cancer Phase II After Interim Check

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for April 8, 2026.

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld Science

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

Hengrui discovers new Nav1.8 blockers

BioWorld Science

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...

News in brief

BioWorld Asia

BioWorld Asia briefs for April 7, 2026

Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis

BioWorld Science

Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...